Welcome to our dedicated page for Cue Biopharma news (Ticker: CUE), a resource for investors and traders seeking the latest updates and insights on Cue Biopharma stock.
Cue Biopharma, Inc. reports developments in clinical-stage immunology therapeutics and immune-modulating biologics. Company updates center on its Immuno-STAT platform, the autoimmune and inflammatory disease candidate CUE-401, a clinical-stage dual-mechanism anti-IgE antibody for allergic diseases, and collaboration activity involving B cell depletion programs such as CUE-501.
Recurring news also covers leadership changes, inducement equity awards, shareholder-approved capital actions, research presentations, milestone payments, licensing activity, and other corporate matters tied to Cue Biopharma's Nasdaq-listed common stock and clinical-stage operating model.
On November 19, 2020, Cue Biopharma (CUE) announced the extension of its research collaboration with Merck, originally established in 2017, aimed at developing therapies for type 1 diabetes and another autoimmune disease. This extension is supported by promising preclinical data and will provide Cue Biopharma with additional financial research support to further explore biologics aimed at identifying clinical candidates. The company emphasizes the potential of its Immuno-STAT™ platform in targeting T cells effectively within the body.
Cue Biopharma, Inc. (Nasdaq: CUE) reported a business update for Q3 2020, highlighting progress in the Phase 1 trial of CUE-101, now entering cohort 7 dosing at 8mg/kg. The company recorded collaboration revenue of $704,000, down from $984,000 in Q3 2019. Operating expenses rose to $10.8 million, driven by increased clinical activities and R&D costs. Net loss was $10.0 million, compared to a loss of $7.0 million in the prior year. As of September 30, 2020, Cue Biopharma held $91.8 million in cash and marketable securities, expected to fund operations into Q2 2022.
Cue Biopharma (Nasdaq: CUE) has announced participation in two upcoming virtual healthcare conferences: the Stifel Virtual Healthcare Conference on November 18, 2020, and the Jefferies Virtual London Healthcare Conference on November 19, 2020. Presentations will cover the company's Immuno-STAT™ platform, ongoing Phase 1 trial of CUE-101 for HPV16-driven head and neck cancer, and highlight future milestones. Webcasts for both events will be available on Cue Biopharma's website.
Cue Biopharma (Nasdaq: CUE) announced a conference call on November 17, 2020, at 4:30 p.m. EST, to update stakeholders on its business progress. The executive team will discuss findings from cohorts 4, 5, and 6 of its ongoing Phase 1 clinical trial of CUE-101, targeting HPV16-driven head and neck cancer. The call will also cover advancements in technology platforms, pipeline updates, and strategic milestones. Access to live and archived versions of the event will be available on the company's website.
Summary not available.
Summary not available.
Cue Biopharma (CUE) has appointed Tamar Howson to its board of directors, enhancing its business development capabilities. Howson, a veteran in the biopharmaceutical industry with over 30 years of experience, has held significant roles in renowned companies. Her expertise is anticipated to significantly aid Cue Biopharma's corporate development efforts in targeted immunotherapy. This leadership change aims to strengthen the company's strategic execution and foster growth as it advances its proprietary platform, Immuno-STAT™, designed to engage targeted T cells effectively.
On September 15, 2020, Cue Biopharma announced the publication of groundbreaking preclinical data in Nature Methods focusing on their Immuno-STAT platform, which utilizes dimeric protein scaffolds for targeted detection of tumor antigen-specific T cells. This innovative immuno-positron emission tomography (immunoPET) approach enhances the ability to visualize T cells within tumors, potentially transforming treatment methodologies for cancer and other diseases. The feasibility of using these techniques for prognostics and diagnostics was also highlighted, showcasing strong clinical implications.
Cue Biopharma (NASDAQ: CUE) announced its participation in several healthcare conferences, including the Baird Global Healthcare Conference on September 9, Morgan Stanley Global Healthcare Conference on September 17, and Oppenheimer & Co. Fall Healthcare Life Sciences and MedTech Summit on September 23, 2020. The company will present its Immuno-STAT™ platform and updates on its pipeline, focusing on its lead candidate CUE-101 for HPV16-driven head and neck cancer. For more details, visit www.cuebiopharma.com.
Cue Biopharma (CUE) reported positive progress in its Phase 1 trial for CUE-101, aimed at treating HPV+ head and neck cancer. The company successfully completed dosing cohorts 4 and 5 and is moving to cohort 6. Financially, Cue Biopharma reported $1.1 million in collaboration revenue for Q2 2020, with R&D expenses increasing to $8.1 million, reflecting growing clinical costs. As of June 30, 2020, the company has $85 million in cash and marketable securities, ensuring funding for ongoing development through 2022.